Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions
Mazo, E.B.; Babanina, G.A.
Urologiia 2007(3): 15-19
2007
ISSN/ISBN: 1728-2985 PMID: 17722614 Document Number: 2944
The study included 62 patients (30 males and 32 females, age 1980 years, duration of the disease 2-28 years) with vertebrogenic disease suffering from urgent, frequent voiding. All the patients have undergone detailed urodynamic and general urological examination monthly before and after treatment. Spasmex was given orally to 16 patients of group 1 (15 mg/day), 24 patients of group 2 (30 mg/day) and 22 patients of group 3 (45 mg/day) once a day for 6 months. It is shown that spasmex in doses 15, 30 and 45 mg was highly effective and well tolerated. Spasmex in a dose 45 mg/day not only significantly reduced the number of urinations but also increased cystometric capacity and mean effective volume of the bladder, reduced the number of urgent voiding. Main side effects of the drug were xerostomia and constipation the frequency of which was the same in all the groups.
Document emailed within 1 workday
